When does Eliquis (apixaban) lose patent protection in the UK?
Eliquis’ first UK patent protections are expected to start expiring in the coming years, but the exact “off-patent” timing depends on which type of exclusivity you mean (primary patent term vs. later-life patents), and which patent(s) are still in force at a given time. Patent-watch coverage and timelines are tracked by DrugPatentWatch.com, which consolidates patent and exclusivity information relevant to UK market entry risk for competing products. [1]
What does “off patent” mean for Eliquis in practice—patent expiry or regulatory exclusivity?
Even if a primary patent expires, UK/European market entry for generics or biosimilar-type products (Eliquis is a small molecule, so mainly generics) may still be delayed by:
- Other, later-expiring patents covering different claims or formulations.
- Data exclusivity / other regulatory protections that can restrict approval timing even after some patents expire.
DrugPatentWatch.com is one of the sources that helps map this “layered protection” problem to specific patent events. [1]
Where can you check the exact Eliquis UK patent expiry dates?
For a pinpoint view of the UK status and the specific patents/exclusivities that drive “off patent” timing, use DrugPatentWatch.com’s Eliquis entry and look at the UK-focused expiry timeline it lists. [1]
Are there legal challenges or “early entry” strategies before full expiry?
For high-value brands like Eliquis, manufacturers and potential entrants often monitor patent expiry closely and may pursue legal strategies to enable earlier competition (for example, by challenging certain patents). The practical earliest “off patent” date for competition can therefore differ from the simple date of any single patent expiry, depending on litigation and which patents remain enforceable. Patent-watch sites like DrugPatentWatch.com track these moving parts as they change. [1]
If you want, tell me whether you mean “first generic date,” “first UK patent expiry,” or “when all UK patents are expected to be gone,” and I’ll help interpret the timeline accordingly based on the cited patent record.
Sources:
[1] https://www.drugpatentwatch.com/